<DOC>
	<DOCNO>NCT00121732</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) E7974 administer intravenous bolus dose Days 1 , 8 , 15 28-day cycle ( Arm A ) Days 1 8 21-day cycle ( Arm B ) patient solid tumor progress follow effective therapy effective therapy exists .</brief_summary>
	<brief_title>An Open-Label Study E7974 Administered Days 1 , 8 , 15 28-Day Cycle Days 1 8 21-Day Cycle Patients With Solid Malignancies</brief_title>
	<detailed_description>This two-arm , open-label , non-randomized , dose-escalation study determine MTD E7974 administer intravenous bolus dose Days 1 , 8 , 15 28-day cycle ( Arm A ) Days 1 8 21-day cycle ( Arm B ) patient solid tumor progress follow effective therapy effective therapy exists . Response progression evaluate study use Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients meet inclusion criterion none exclusion criterion eligible entry study : 1 . Patients must pathologically diagnose , histologically cytologically confirm solid tumor progress follow effective therapy effective therapy exists ( include surgery radiation therapy ) . 2 . Patients must &gt; = 18 year age . 3 . Patients must Eastern Cooperative Oncology Group ( ECOG ) status 0 1 . 4 . Patients must life expectancy &gt; = 3 month . 5 . Patients must adequate renal function evidence serum creatinine &lt; = 1.5 mg/dL creatinine clearance &gt; = 40 mL/minute ( min ) . 6 . Patients must adequate bone marrow function evidence absolute neutrophil count &gt; = 1,500/µL , hemoglobin &gt; = 9 g/dL ( may transfuse ) , platelet count ( transfuse ) &gt; = 100,000/µL . 7 . Patients must adequate liver function evidence bilirubin &lt; = 1.5 mg/dL alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; = 3 time upper limit normal ( ULN ) , unless relate liver involvement tumor , case &lt; = 5.0 time ULN . 8 . Patients must willing able sign write informed consent able comply study protocol duration study . 9 . Patients must willing able undergo blood draw urine sample PK Cycle 1 . 10 . Patients may either measurable nonmeasurable disease . The presence one follow criterion disqualify patient enrollment study : 1 . Patients receive chemotherapy within three week E7974 treatment start ( 6 week nitrosourea ) . 2 . Patients recover chemotherapyrelated therapyrelated toxicity &lt; = Grade 1 study entry ( exclude Grade 2 alopecia ) . 3 . Patients receive radiotherapy &lt; = 3 week prior study enrollment , whose marrow exposure exceed 25 % recover toxic effect treatment prior study enrollment ( except alopecia ) . 4 . Patients major surgery without full recovery major surgery within three week E7974 treatment start . 5 . Patients primary brain tumor metastasis study entry must control &gt; = 1 month previous treatment , include radiation therapy corticosteroid . 6 . Women pregnant breastfeeding . 7 . Women childbearing potential either positive pregnancy test screening pregnancy test . 8 . Women childbearing potential unless ( 1 ) surgically sterile , ( 2 ) physiologically postmenopausal &gt; 12 month , ( 3 ) use adequate measure ( include barrier method ) contraception . 9 . Fertile men partner willing use contraception . 10 . Patients positive history Human Immunodeficiency Virus ( HIV ) and/or active hepatitis B active hepatitis C study entry . 11 . Patients severe , uncontrolled intercurrent illness infection . 12 . Patients medically uncontrolled cardiovascular illness define unstable angina , &gt; = symptomatic Grade II New York Heart Association ( NYHA ) Classification congestive heart failure ( CHF ) , myocardial infarction within six month prior study entry . 13 . Patients receive organ allograft require immunosuppressive therapy . 14 . Patients receive investigational drug include immunotherapy , gene therapy , hormone therapy , biologic therapy , chemotherapy within threeweek period prior E7974 treatment start ; patient must recover previous major therapyrelated toxicity ( Grade 3 4 ) &lt; = Grade 1 study entry . 15 . Patients current history peripheral neuropathy &gt; CTC Grade 2 ( e.g. , diabetic chemotherapyinduced neuropathy ) . 16 . Patients history uncontrolled seizure . 17 . Patients mark baseline prolongation QT/QTc interval ( QTc interval &gt; 470 ) use Fridericia method main method QTc analysis . 18 . Patients significant disease disorder , Investigator 's opinion , would exclude study . 19 . Patients allergy hypersensitivity hemiasterlin base product analogue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>